help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arrer, E.
Right arrow Articles by Patsch, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arrer, E.
Right arrow Articles by Patsch, W.

Journal of Clinical Endocrinology & Metabolism, Vol 81, 2508-2511, Copyright © 1996 by Endocrine Society

ARTICLES

Treatment of prostate cancer with gonadotropin-releasing hormone analogue: effect on lipoprotein[a]

E Arrer, A Jungwirth, D Mack, J Frick and W Patsch
Department of Laboratory Medicine, Landeskrankenanstalten Salzburg, Austria.

Because of its association with cardiovascular disease, lipoprotein[a] (Lp[a]) has attracted the interest of the medical community. Even though serum concentrations of Lp[a] are mainly controlled by the apolipoprotein[a] gene locus, hormonal and metabolic factors, including manipulations of sex hormone levels, have been associated with changes in Lp[a] levels. We report here that the GnRH analog buserelin reduced concentrations of Lp[a] by 48% in elderly males suffering from cancer of the prostate. In contrast, apolipoprotein B levels increased during treatment, whereas other lipid factors, including serum cholesterol, triglyceride, high and low density lipoprotein cholesterol, and apolipoprotein A-I, were not affected. Although the study does not exclude a specific Lp(a)-lowering effect of buserelin, our results suggest that GnRH analogs may reduce Lp[a] levels in the circulation.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
T. Nishiyama, F. Ishizaki, T. Anraku, H. Shimura, and K. Takahashi
The Influence of Androgen Deprivation Therapy on Metabolism in Patients with Prostate Cancer
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 657 - 660.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
F. C. W. Wu and A. von Eckardstein
Androgens and Coronary Artery Disease
Endocr. Rev., April 1, 2003; 24(2): 183 - 217.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. R. Smith, J. S. Finkelstein, F. J. McGovern, A. L. Zietman, M. A. Fallon, D. A. Schoenfeld, and P. W. Kantoff
Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 599 - 603.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
G. Ricci, G. Tamaro, R. Simeone, E. Giolo, G. Nucera, F. De Seta, and S. Guaschino
Lipoprotein(a) changes during natural menstrual cycle and ovarian stimulation with recombinant and highly purified urinary FSH
Hum. Reprod., March 1, 2001; 16(3): 449 - 456.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. von Eckardstein, S. Kliesch, E. Nieschlag, A. Chirazi, G. Assmann, and H. M. Behre
Suppression of Endogenous Testosterone in Young Men Increases Serum Levels of High Density Lipoprotein Subclass Lipoprotein A-I and Lipoprotein(a)
J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3367 - 3372.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society